Johnson & Johnson at RBC Capital Markets Global Healthcare Conference Transcript
To have here Michael Bodner, company, Group Chair, EP and Neurovascular from J&J MedTech as well as Ryan and Lauren from Investor Relations. So thank you so much for being here -- just a quick background. Michael has been with J&J for almost 10 years, previously served as wide President of Biosense Webster.
He also led the integrations of Abiomed and Shock and he now oversees [to] high-growth, high innovation franchises within J&J's cardiovascular portfolio. So Michael, thank you so much for being here today.
Thank you for inviting me.
Questions & Answers
Okay. Great. So maybe we'll dive into the EP market because that's definitely the hot topic here. I think you've described the global market at the $16 billion opportunity, growing about 12%, 13%. And it is still highly underpenetrated.
Maybe you can talk to us about where you see the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
